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Abstract
Loss of ABCA1 activity in Tangier disease (TD) is associated with abnormal apoB lipoprotein
(Lp) metabolism in addition to the complete absence of high density lipoprotein (HDL). We used
hepatocyte-specific ABCA1 knock-out (HSKO) mice to test the hypothesis that hepatic ABCA1
plays dual roles in regulating Lp metabolism and nascent HDL formation. HSKO mice

recapitulated the TD lipid phenotype with postprandial hypertriglyceridemia, markedly
decreased LDL, and near absence of HDL. Triglyceride (TG) secretion was 2-fold higher in
HSKO compared with wild type mice, primarily due to secretion of larger TG-enriched VLDL
secondary to reduced hepatic phosphatidylinositol 3-kinase signaling. HSKO mice also displayed
delayed clearance of postprandial TG and reduced post-heparin plasma lipolytic activity. In
addition, hepatic LDLr expression and plasma LDL catabolism were increased 2-fold in HSKO
compared with wild type mice. Last, adenoviral repletion of hepatic ABCA1 in HSKO mice
normalized plasma VLDL TG and hepatic phosphatidylinositol 3-kinase signaling, with a partial
recovery of HDL cholesterol levels, providing evidence that hepatic ABCA1 is involved in the
reciprocal regulation of apoB Lp production and HDL formation. These findings suggest that
altered apoB Lp metabolism in TD subjects may result from hepatic VLDL TG overproduction
and increased hepatic LDLr expression and highlight hepatic ABCA1 as an important regulatory
factor for apoB-containing Lp metabolism.
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Introduction
ABCA1 (ATP-binding cassette transporter A1) is indispensable in the initial steps of high
density lipoprotein (HDL)2 formation and the process of reverse cholesterol transport from
peripheral tissues to the liver. ABCA1 is expressed in many cells; however, hepatocytes make
the single most important contribution to plasma HDL concentration (1,–3). Mutations in ABCA1
in humans cause Tangier disease (TD), an autosomal recessive disorder characterized by severe
HDL deficiency, rapid plasma clearance of HDL and apoA-I, sterol deposition in tissues, and
premature coronary atherosclerosis (4,–7).
In addition to HDL deficiency, TD subjects have significantly elevated plasma TG and a 50%
reduction in LDL cholesterol concentrations (4, 8). The TG phenotype in TD disease is
complicated, with most, but not all, TD subjects displaying elevated fasting or postprandial TG
elevations (9). Clee et al. (8) reported an inverse relationship between dysfunctional ABCA1
alleles and plasma TG concentrations. In addition, data from case reports of 59 Tangier patients
show variable TG concentrations, with mean, median, minimum, and maximum concentrations
of 210, 175, 40, and 580 mg/dl, respectively (4). The underlying mechanisms for the increased
plasma TG and decreased LDL concentrations in TD subjects have not been established. In one
study, apoA-II enrichment of VLDL of TD subjects was proposed to result in reduced reactivity
of VLDL with lipoprotein lipase (LPL) (9, 10). Another study suggested that ABCA1-dependent
cholesterol efflux decreases VLDL secretion from murine hepatocytes by limiting cholesterol
availability for VLDL assembly (11). However, whether deficiency of ABCA1 is associated with
increased apoB lipoprotein secretion in vivo is unknown.
Recently, we reported that silencing of ABCA1 in rat hepatoma cells is associated with PI3Kdependent enhanced secretion of TG-enriched VLDL (12), suggesting a potential role of hepatic
ABCA1 expression in VLDL assembly and secretion. To determine whether hepatic ABCA1
expression affects VLDL secretion in vivo, we used loss of function and gain of function
strategies with hepatocyte-specific gene targeting of ABCA1 and adenoviral overexpression of

human ABCA1, respectively. We demonstrate that targeted inactivation of hepatic ABCA1
increases VLDL production and LDL clearance, recapitulating the TD lipid phenotype, and that
adenoviral rescue of ABCA1 reverses the elevated plasma TG phenotype. These studies
highlight a novel and important role for hepatic ABCA1 in regulating apoB Lp metabolism.

EXPERIMENTAL PROCEDURES
Animals and Diet

Generation and genotyping of HSKO (albumin Cre+, ABCA1flox/flox), hetero-HSKO (albumin
Cre+, ABCA1flox/+), and wild type control (albumin Cre+, ABCA1+/+) mice were performed as
described previously (1). The HSKO mice used for this study were backcrossed into the
C57BL/6 background and determined to be >99% in that background by genome-wide screens
using 134 single nucleotide polymorphisms that were polymorphic between the C57BL/6 and
129/SvEv strains and spaced ∼20 megabase pairs across the mouse genome. HSKO mice were
also crossed with LDL receptor knock-out (LDLrKO) mice (Jackson Laboratories). The mice
were housed in the Wake Forest University Health Sciences animal facility with a 12-h light (6
a.m. to 6 p.m.)/12-h dark cycle and maintained on a chow diet (Prolab RMH3000 rodent diet,
LabDiet). In most studies, 12–16-week-old male mice were used. In one study, 8-week-old mice
were fed an HF diet containing 45% calories from fat (90% from lard), 35% calories from
carbohydrate (50% from sucrose), and 20% from protein for 8 weeks. All protocols and
procedures were approved by the Wake Forest University Health Sciences Animal Care and Use
Committee.
Analysis of Plasma and Liver Lipids

Plasma was collected by tail bleeding of 6-h fasted or non-fasted mice. To determine lipoprotein
lipid distribution, pooled plasmas were either fractionated by two Superose 6 FPLC columns (1 ×
30 cm) in series (flow rate 0.5 ml/min; Fig. 1D) (1) or by a high resolution Superose 6TM FPLC
column (10/300GL, Amersham Biosciences; flow rate 0.5 ml/min; see Fig. 6, D–F). Fractions
eluting from the columns were used for enzymatic determination of total plasma cholesterol
(TPC) and TG. In Fig. 5F, TPC distribution in whole plasma was determined using a high
resolution Superose 6 column (1 × 30 cm) and an online cholesterol analyzer (Elite La Chrome,
Hitachi). Total cholesterol and triglyceride concentrations were determined by an enzymatic
colorimetric assay using a commercial kit (Chol and Trig/GB, Roche Applied Science). For the
free fatty acid composition analysis, lipid extracts from liver were fractionated into cholesteryl
ester, TG, and phospholipid bands by TLC, and then each fraction was methylated and analyzed
by gas-liquid chromatography (13). For the quantification of hepatic free fatty acid content, liver
lipid extracts (Bligh-Dyer extraction) were dried down under N2, solubilized with 1% Triton X100 (14), and then quantified using a commercial NEFA assay kit (Wako).
Liver Perfusion

Recirculating liver perfusion was carried out as described previously (15). Ten ml of perfusate
medium with erythrocytes (10% hematocrit) were pumped through livers at 1 ml/min for 3 h.
Every 30 min during perfusion, 1 ml of perfusate was collected, and perfusate volume was

replenished with fresh perfusate. The collected perfusate was centrifuged (1,100 × g for 30 min)
to pellet erythrocytes and perfusate plasma was then assayed for TG concentration using an
enzymatic assay as described previously (15). A plot was then made of perfusion time versus TG
concentration for each animal; lipid accumulation rates were obtained from the slope of the line
of best fit, determined by linear regression analysis using GraphPad Prism 5® software
(GraphPad Software, Inc., San Diego, CA).
VLDL Subfractionation and Particle Size Analysis

For plasma lipoprotein fractionation, 200 μl of pooled plasma (n = 3 per genotype) was first
adjusted to d = 1.10 g/ml with solid KBr in 4 ml of saline. Plasma was overlaid with 3 ml of d =
1.065 g/ml NaBr, 3 ml of d = 1.02 g/ml NaBr, and 3 ml of d = 1.006 g/ml NaCl in a Beckman
SW40 centrifuge tube. After ultracentrifugation at 40,000 rpm for 148 min at 20 °C, VLDL1 (Sf
> 100) was collected from the top 1 ml of the gradient. Following a subsequent
ultracentrifugation at 37,000 rpm for 18 h at 15 °C, VLDL2 (Sf 20–100) and other lipoproteins
were collected from the top into 11 fractions (1 ml each). TG concentration in each fraction was
determined by enzymatic assay. VLDL size from an equal volume of pooled VLDL1 and
VLDL2 was analyzed using a Zetasizer Nano S® dynamic light scattering instrument (Malvern).
Particle sizes are reported as median peak diameter using volume analysis.
In Vivo Determination of VLDL TG and ApoB Secretion Rate

After a 4-h fast, male mice (n = 3 of each genotype) were anesthetized and injected in the
peritoneal cavity with poloxamer 407 (1,000 mg/kg; Sigma), to block lipolysis and with
[3H]oleate (5 μCi/g body weight) and [35S]Cys/Met (7 μCi/g body weight) as tracers of TG and
protein synthesis, respectively (16, 17). To study the effect of in vivo inhibition of PI3K on
VLDL TG and apoB production, mice were injected with the PI3K inhibitor wortmannin (1.5
μg/g body weight) 1 h prior to detergent injection as described previously (18). Fifty μl of blood
were collected from anesthetized mice by retro-orbital bleeding at 0, 1, 2, and 4 h after injection.
Plasma was harvested from the blood samples and used to quantify TG mass by enzymatic assay
and radiolabel incorporation into newly secreted VLDL TG and apoB. Briefly, plasma was lipidextracted, TG was fractionated by thin layer chromatography, and radiolabel in the TG band was
quantified by liquid scintillation counting. TG secretion rates were derived from the slope of the
line of best fit of time versus plasma [3H]TG plots for each individual animal using GraphPad
Prism 5. To measure secretion of newly synthesized apoB, 10 μl of the terminal plasma sample
were immunoprecipitated with goat anti-human apoB antiserum (5 μg) in buffer containing 1%
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 0.2% bovine serum albumin, protease
inhibitors, and phosphatase inhibitor (i.e. immunoprecipitation buffer). After 18 h of incubation
of the samples with rotation at 4 °C, 20 μl of protein G beads (50:50 slurry; Amersham
Biosciences) were added for 2 h. Beads were collected by centrifugation at 10,000 rpm for 10 s
and washed three times with lysis buffer. Proteins were eluted from the beads by heating (70 °C
for 10 min) in SDS-PAGE sample buffer and fractionated by 4–8% gradient SDS-PAGE. Gels
were then dried and visualized with a PhosphorImager.
Plasma Lipase Activity

To prepare post-heparin plasma, mice were first anesthetized, and then 300 units/kg heparin was
injected via the tail vein (n = 7–8 per genotype). Blood was collected by cardiac puncture 15 min
after heparin injection using a heparin-coated syringe. Hepatic lipase (HL) and LPL activities
were measured in the post-heparin plasma (20 μl) using a radiolabeled triolein-Triton X-100
mixed micellar substrate as described previously (19). HL activity was measured as the activity
in the presence of 1 m NaCl or in the absence of apoC-II activator. LPL activity was calculated
as total activity minus HL activity. Lipolytic activities were expressed as μmol of fatty acid
released/h/ml of plasma.
Postprandial Lipemia Study

Age- and body weight-matched male mice (n = 4 of each genotype) were fasted for 4 h,
beginning at 6:00 a.m. For basal level TG measurement, 20 μl of blood was collected from the
tail vein, prior to oral administration of 150 μl of olive oil. Subsequent bleeds followed at 0.5, 1,
2, 4, and 8 h post-gavage. Plasma concentrations of triglycerides were determined by an
enzymatic assay as described above.
Hepatic PI3K Activation

To determine the activation of hepatic PI3K after acute insulin injection, mice were anesthetized
with ketamine/xylazine, the portal vein was exposed, and 5 units insulin/kg body weight were
injected. Five min later, liver was isolated and snap-frozen in liquid N2 and kept at −80 °C until
analyses were performed. Liver homogenates were prepared in the presence of
protease/phosphatase inhibitor mixture (Sigma) and subsequently used for Western blot analysis
of total PI3K p85 and phospho-PI3K 85 expression. For the fast/refeeding studies, mice were
moved to individual clean cages (with free access to water) and fasted for 15 h, re-fed for 2 h,
and then fasted for an additional 2 h to allow clearance of chylomicrons (i.e. refed group) before
the mice were euthanized for liver collection. The fasted group was fasted for a total of 19 h
before liver collection.
Primary hepatocytes from WT and HSKO mice were isolated as described previously (1) and
used for PI3K activation and TG secretion studies. Briefly, the portal vein was cannulated, and
the liver was perfused at a rate of 4 ml/min with a calcium- and magnesium-free buffer (10 mm
HEPES, pH 7.4, 0.5 mm EDTA), followed by a collagenase solution (0.3 mg/ml collagenase I,
Worthington). Hepatocytes released from the liver capsule and intact hepatocytes were isolated
by two rounds of centrifugation at 50 × g for 5 min. Cells were plated into 35-mm dishes
precoated with collagen (Sigma) at a density of 0.5 × 106 cells/dish in William's E medium
containing 5% fetal bovine serum, 2 mm l-glutamine, 0.1 nm insulin (Sigma), 100 units/ml
penicillin, and 100 μg/ml streptomycin. The PI3K activation was evaluated as mentioned above,
and TG secretion were measured as we described previously (12).
LDL Turnover

LDL was isolated from 2 ml of LDLrKO plasma by sequential ultracentrifugation (Beckman
Instruments, Palo Alto, CA) at d = 1.019–1.063 g/ml. The isolated mouse LDL preparation was
radiolabeled with 125I using the iodine monochloride method (20). Specific activity of the 125ILDL tracer was 308 cpm/ng protein, trichloroacetic acid-precipitable 125I radioactivity was 97%,

and lipid radiolabeling was negligible. The 125I-LDL tracer also eluted with authentic LDL on a
Superose 6 FPLC column. Recipient mice (n = 4/genotype) were anesthetized with isoflurane,
and 0.5 × 106 cpm of the radiolabeled tracer were injected via the tail vein. Blood samples (30
μl) were drawn at 2, 10, and 30 min and 1, 3, 6, and 22 h after tracer injection by retro-orbital
bleeding of anesthetized mice. 125I-apoB (apoB-48 plus apoB-100) was precipitated from 15 μl
of plasma using isopropyl alcohol, with human LDL (100 μg) as a carrier (17), and 125I
radiolabel was determined by γ-scintillation spectrometry. Turnover curves were plotted as a
percentage of the 2-min plasma radioactivity remaining in plasma after injection of the tracers.
Fractional catabolic rate (FCR) was calculated for individual plasma die-away curves using a
biexponential curve-fitting program in GraphPad Prism 5.
Adenoviral Overexpression of hABCA1

Adenoviruses expressing full-length human ABCA1 (Ad-ABCA1) and alkaline phosphatase
(Ad-AP) were generated was previously described (21, 22). The titration of recombinant
adenovirus was performed using a commercial titration kit (Adeno-XTM Rapid Titer kit,
Clonetech). Preinfection blood samples of non-fasted WT and HSKO mice fed a HF diet for 8
weeks were collected at 9:00 a.m. via tail vein bleeding. Adenoviral vectors were diluted in
sterile PBS and intravenously delivered to WT and HSKO mice (n = 4/group) at a dose of 3 ×
108 infectious units/mouse (21, 22). Three days after Ad-AP or Ad-ABCA1 infection, blood and
liver samples were collected at 9:00 a.m. from the non-fasted WT and HSKO recipient mice.
Real-time PCR Analysis

Total RNA was isolated from liver of age-matched male mice using TRIzol (Invitrogen), and
real-time PCR was performed as described previously (23). Primer sequences for ABCA1,
ABCG1, SRBI, SREBP2, LXRα, LXRβ, and GAPDH expression were the same as reported
previously (23). Sequences for ABCG5, LRP, LDLr, SREBP1c, PPARα, PPARγ, PGC1α, and
FXRα are summarized in supplemental Table 1. GAPDH was used as an endogenous control.
Western Blotting

Mouse liver extract was prepared by homogenizing ∼500 mg of frozen liver with a Polytron
homogenizer in radioimmune precipitation lysis buffer containing protease inhibitor and
phosphatase inhibitor mixture (Sigma). Western blots were performed as previously described
(1). Polyclonal antibodies targeting phospho-PI3K p55/p85, phospho-Akt (Ser473), and total Akt
were purchased from Cell Signaling Technology. Antibodies against human apoB and mouse
apoA-I were purchased from Biodesign. Antibody against endothelial lipase was purchased from
Cayman Chemical. Polyclonal antibodies directed at LDLr and apoE were provided by Dr.
Liqing Yu (Wake Forest University Health Sciences).
Statistics

Results are presented as means ± S.E. Data were statistically analyzed using Student's t test or
one-way analysis of variance with Tukey's multiple comparisons.

RESULTS
Targeted Deletion of Hepatocyte ABCA1 Results in Postprandial Hypertriglyceridemia

HSKO mice were generated by crossing ABCA1-floxed mice with albumin Cre transgenic mice
as described previously (1). To determine the potential effect of hepatocyte ABCA1 expression
on plasma TG concentrations, both fasted and non-fasted mice were studied. There was no
significant difference in TG levels in fasting WT and HSKO mice (Fig. 1A); however, in the
non-fasting state, there was a significant elevation in plasma TG concentrations with successive
deletion of hepatic ABCA1 alleles (63 ± 4, 82 ± 4, and 152 ± 13 mg/dl for WT, heterozygous,
and homozygous HSKO, respectively) (Fig. 1B). Plasma apoB48 levels also demonstrated a
stepwise increase with loss of hepatic ABCA1 expression, whereas apoB100 levels displayed a
decrease in abundance that was particularly dramatic in homozygous HSKO mice (Fig. 1C). To
further characterize the lipoprotein response in non-fasted mice, pooled plasma was fractionated
by FPLC. In addition to a striking reduction of HDL cholesterol as described previously (1), loss
of hepatic ABCA1 gene function caused a dose-dependent decrease in LDL cholesterol and LDL
TG and an increase in VLDL cholesterol and VLDL TG (Fig. 1D). Western blot analysis of
FPLC fractions corresponding to the major lipoprotein classes (Fig. 1E) revealed that hepatic
inactivation of ABCA1 caused a gene dose-dependent increase in apoB48 and -100 in VLDL but
a decrease in LDL. Thus, the whole plasma Western blot results in Fig. 1C can be explained by
the increase of plasma apoB in VLDL and the decrease in LDL that occurs in HSKO mice
relative to WT mice. It was also notable that inactivation of ABCA1 reduced apoE in the LDL
and HDL fractions. As expected, apoA-I in HDL was reduced in the HSKO mice (Fig. 1E).
Collectively, these data demonstrate that hepatocyte-specific inactivation of ABCA1 induces
postprandial hypertriglyceridemia, characterized by an increase in plasma VLDL and a decrease
in plasma LDL, recapitulating the TD lipid phenotype (10, 24).
Deletion of Hepatocyte ABCA1 Increases Hepatic TG Secretion and Reduces Post-heparin Plasma Lipolytic
Activity

To determine whether hepatic production of TG contributes to the elevated levels of plasma TG
in HSKO mice, we performed two studies. First, we measured hepatic TG mass secretion using
isolated recirculating liver perfusion. The TG accumulation rate in liver perfusate of HSKO mice
was twice that of WT mice (3.40 ± 0.20 versus 1.87 ± 0.07 μg/g liver/min; p < 0.001), suggesting
hepatic TG mass secretion is increased in the absence of ABCA1 (Fig. 2A). In the second
experiment, TG and apoB production were measured in vivo in the presence of the detergent
poloxamer 407, to block TG lipolysis. Radiolabeled precursors ([3H]oleic acid and [35S]Met/Cys)
were injected with the detergent, and the appearance of newly synthesized and secreted TG and
apoB was monitored. In agreement with the liver perfusion data, the rate of TG secretion was
2.6-fold higher in HSKO mice relative to WT mice (Fig. 2B, top). Analysis of total radiolabeled
apoB in the terminal plasma sample showed a 1.6-fold increase (1.4-fold in apoB100 and 1.73fold in apoB48) in HSKO versus WT mice (Fig. 2B, bottom). Collectively, these data suggest
that deficiency of hepatic ABCA1 expression increases hepatic TG secretion.
To determine whether reduced plasma lipolytic activity also contributed to the elevation of
plasma TG in HSKO mice, HL and LPL activity were measured in post-heparin plasma using

[3H]triolein micelles as substrates. HSKO mice displayed a 50% reduction in total lipase activity
relative to WT mice (18.86 ± 1.10 versus 10.10 ± 0.40 μmol of fatty acid released/h/ml of
plasma), which was due to a ∼30% reduction in HL activity (11.10 ± 0.64 versus 7.69 ± 0.28)
and a ∼70% reduction in LPL activity (7.76 ± 0.58 versus 2.4 ± 0.25) (Fig. 2C). In agreement
with the reduced lipase activity, HSKO mice displayed delayed clearance of an oral fat load
compared with WT mice (Fig. 2D). TPC during the oral fat load was constant for heterozygote
and WT mice but showed a slight increase in HSKO mice, presumably due to the delayed
clearance of chylomicron remnants and the low basal cholesterol concentrations in HSKO mouse
plasma. Taken together, these data suggest that, in addition to effects on TG secretion, hepatic
ABCA1 deficiency also affects the clearance of apoB lipoproteins.
To address whether hepatic deletion of ABCA1 altered hepatic lipid homeostasis, liver lipid
content was analyzed. Total cholesterol (2.39 ± 0.15 versus 2.84 ± 0.3 μg/mg liver, p = 0.20),
free cholesterol (1.62 ± 0.15 versus 1.66 ± 0.15 μg/mg liver, p = 0.87), and TG content (13.41 ±
2.02 versus 15.17 ± 3.45 μg/mg liver, p = 0.65) were similar for WT versus HSKO mice,
respectively (Fig. 3A). Expression of hepatic lipid metabolism-related genes (Fig. 3B), fatty acid
composition of liver lipids (Fig. 3C), and total free fatty acid content (Fig. 3D) were similar
between the two genotypes of mice. Together, these data indicate that, despite alterations in TG
secretion and lipolytic activity associated with inactivation of hepatic ABCA1, no major changes
occurred in hepatic lipid content.
Loss of Hepatocyte ABCA1 Expression Increases Nascent VLDL Size and Attenuates PI3K Signaling

Overproduction of VLDL TG occurs in diabetes and metabolic syndrome and is associated with
an increase in VLDL particle size (25, 26). To determine whether increased hepatic TG secretion
in HSKO mice is associated with secretion of larger, more buoyant VLDL, pooled plasma (n = 3)
was fractionated by density gradient ultracentrifugation into VLDL1 (Sf = 100–400) and VLDL2
(Sf = 20–100). As anticipated, there was a significant increase of VLDL1-TG in HSKO mice
relative to WT mice, suggesting secretion of larger VLDL particles (Fig. 4A). In support of this
result, VLDL size (measured by dynamic laser light scattering) was larger in HSKO (79.1 ± 0.4
nm) compared with WT mice (42.5 ± 3.1 nm) (Fig. 4B). Examination of VLDL (VLDL1 and -2)
apolipoprotein content by Western blot analysis using an equivalent amount of VLDL protein (4
μg) revealed that VLDL from HSKO mice had more apoB48, apoB100, and apoA-I and less
apoE (apoE/apoB ratio = 0.49 relative to WT) compared with WT mouse VLDL (Fig. 4C).
Previously, we showed that silencing of ABCA1 in rat hepatoma cells was associated with
elevated TG secretion, increased VLDL particle size, and reduced PI3K activation (12). To
examine whether PI3K activation was diminished in livers of HSKO mice, we stimulated the
PI3K pathway by acute insulin administration or by subjecting mice to a fasting/refeeding
protocol. Portal vein injection of insulin (5 units/kg) induced robust phosphorylation of PI3K p85
in WT liver, whereas there was a 28% decrease in HSKO liver (Fig. 5A; WT versus HSKO was 1
versus 0.72 ± 0.008; n = 3 mice/treatment, p = 0.031). In the fasting/re-feeding experiments,
PI3K phosphorylation was reduced 31% in HSKO compared with WT liver (Fig. 5B; 1 versus
0.72 ± 0.004; n = 3 mice per treatment, p = 0.01), and Akt phosphorylation was 63% lower (1
versus 0.36 ± 0.059; n = 3 mice/treatment, p = 0.038). Moreover, in vivo pharmacological
inhibition of PI3K by wortmannin, prior to detergent blockage of lipolysis, had little effect on
plasma TG and secretion of newly synthesized apoB in HSKO mice (Fig. 5C, HSKO ± Wort).

On the other hand, in vivo inhibition of PI3K activation with wortmannin in WT mice resulted in
increased plasma TG as well as apoB secretion (+/+; compare ± Wort), to levels similar to those
observed in HSKO mice (Fig. 5C). Effects of PI3K activation on hepatic TG secretion was also
investigated in primary hepatocytes. Synthesis and secretion of TG from [3H]oleate was almost
3-fold higher in HSKO mice (Fig. 5D). Consistent with in vivo results, phosphorylation of PI3K
p85 was diminished in primary hepatocytes from HSKO mice as compared with WT mice (Fig.
5D). However, hepatic microsomal transfer protein (MTP) mRNA and protein levels were
similar (Fig. 5E), suggesting that up-regulation of MTP is not the basis for increased TG
secretion caused by hepatic ABCA1 deficiency. These data provide mechanistic evidence that
targeted inactivation of hepatic ABCA1 attenuates activation of PI3K, which in turn, contributes
to increased secretion of larger TG-enriched VLDL.
Selective Hepatocyte ABCA1 Deletion Increases Plasma Clearance of LDL

To determine whether loss of hepatic ABCA1 expression contributes to reduced plasma LDL
concentrations by increasing LDL clearance from plasma, we performed turnover studies using
LDL isolated from LDLrKO mice. Isolated LDL was radioiodinated with 125I and intravenously
injected into WT and HSKO recipient mice, after which plasma clearance of the 125I-LDL tracer
was measured. The LDL tracer was removed from plasma more rapidly in HSKO recipient mice
compared with WT mice (Fig. 6A). The FCR (pools/day) of 125I-LDL apoB was significantly (p
< 0.001) higher in HSKO mice than WT mice (5.26 ± 0.28 versus 2.95 ± 0.15) (Fig. 6A).
Surprisingly, hepatic LDLr mRNA (Fig. 6B) and protein (Fig. 6C) abundance were markedly
increased in the absence of hepatic ABCA1, suggesting that hepatic LDLr-mediated clearance
contributed to the higher LDL FCR observed in HSKO mice.
To further explore this hypothesis, we crossed HSKO mice with LDLrKO mice. In the LDLrKO
background, there was still a significant elevation in plasma TG concentrations associated with
successive deletion of hepatic ABCA1 alleles (60.7 ± 2.0, 69 ± 3.9, 93.8 ± 7.0 mg/dl for WT,
heterozygous, homozygous HSKO in LDLrKO background; Fig. 6D, top), similar to the plasma
TG response trend of mice with functional LDL receptors (Fig. 1B). Although total plasma
cholesterol was significantly lower in HSKO mice in the LDLrKO background (Fig. 6D,
bottom), this was due to exclusively to a marked decrease in HDL cholesterol (46 versus 8 mg/dl
in LDLrKO versus LDLrKO, HSKO mice; Fig. 6F). However, in contrast to LDL-replete mice
(Fig. 1D), LDL cholesterol concentrations were similar (106 versus 103 mg/dl in LDLrKO
versus LDLrKO, HSKO mice) (Fig. 6F), suggesting that hepatic LDLr-mediated clearance is the
major cause for reduced LDL concentrations in HSKO mice. There was also a decrease in
scavenger receptor B-I and endothelial lipase expression in HSKO liver (supplemental Fig. 1). In
summary, the significantly lower plasma LDL concentrations in HSKO mice appear to be due to
more rapid plasma clearance of LDL particles, secondary to increased hepatic LDLr expression.
Adenoviral Repletion of ABCA1 Normalizes Plasma TG Concentrations in High Fat-fed HSKO Mice

To determine whether repletion of hepatic ABCA1 would reverse the plasma lipid phenotype of
HSKO mice, we injected intravenously Ad-ABCA1 or Ad-AP (control) into WT and HSKO
mice fed an HF diet for 8 weeks. The HF diet was employed to more closely mimic the human
dietary situation and to increase plasma and liver lipid concentrations. Three days after injection,
Ad-ABCA1 had restored ∼60% of WT hepatic ABCA1 expression in HSKO mice, whereas it

induced a 2-fold increase in hepatic ABCA1 levels in WT mice (Fig. 7A; the anti-ABCA1
antibody was raised using a peptide whose sequence is identical between mouse and human
ABCA1). Consistent with data generated using chow-fed mice (Fig. 6C), hepatic LDLr protein
expression was also higher in HF-fed HSKO mice compared with WT mice; however, in neither
background did short term overexpression strongly impact hepatic LDLr expression. Moreover,
similar to results in chow-fed mice (Fig. 5, A and B), PI3K phosphorylation was reduced in HFfed HSKO mice; however, partial repletion of hepatic ABCA1 in HSKO by adenoviral delivery
of human ABCA1 restored PI3K phosphorylation to a level comparable with levels in AdABCA1-treated WT liver (Fig. 7A). TPC was significantly increased in WT mice injected with
Ad-ABCA1 compared with Ad-AP (Fig. 7B; 251 ± 23 versus 154 ± 3 mg/dl; n = 4) due to
increases in LDL and HDL cholesterol (Fig. 7C). In HSKO mice, Ad-ABCA1 expression
actually decreased TPC concentration (Fig. 7B) by decreasing VLDL cholesterol concentration
to a greater extent than it increased HDL cholesterol (Fig. 7D). Plasma TG concentration was
unchanged in WT mice injected with Ad-ABCA1 versus Ad-AP (Fig. 7B) due to an increase in
VLDL TG and a reciprocal decrease in LDL TG (Fig. 7E). In HSKO mice, Ad-ABCA1 injection
resulted in a normalization of plasma TG concentration to WT levels (Fig. 7B) and a striking
decrease in VLDL TG (Fig. 7F). Because plasma lipase activity was unchanged over the
relatively short time course of the adenovirus experiment (data not shown), it is likely that the
decreased plasma TG levels in HSKO mice treated with Ad- ABCA1 was due to decreased
hepatic TG secretion, not increased TG hydrolysis. Unlike the situation in chow-fed mice in
which hepatic liver lipid content was similar between WT and HSKO mice (Fig. 3A), HF-fed
HSKO mice displayed a paradoxical decrease in hepatic TG and TC content relative to WT mice
(Fig. 7G), and acute repletion of hepatic ABCA1 did not affect hepatic lipid content in either
genotype of mice. These results demonstrate that acute, partial (60%) repletion of hepatic
ABCA1 expression in HSKO mice can normalize plasma TG concentrations within 3 days,
although HDL cholesterol concentrations were not fully recovered to WT levels.

DISCUSSION
It is well established that ABCA1 influences HDL metabolism in humans, mice, and chickens
(27); however, its role in metabolism of apoB-containing lipoproteins remains elusive. In the
present study, we demonstrated that targeted inactivation of ABCA1 in hepatocytes recapitulates
the lipid phenotype of TD subjects, including reduced HDL and LDL cholesterol, and elevated
TG concentrations. We established that part of the lipid phenotype associated with hepatic
ABCA1 deficiency results from an increased secretion of TG-enriched hepatic VLDL via a
PI3K-dependent pathway. We also documented decreased post-heparin lipolytic activity and
increased hepatic LDLr expression, resulting in a net increase in clearance of LDL from the
circulation. Furthermore, elevated plasma VLDL TG was rescued by adenoviral expression of
human ABCA1, demonstrating the existence of a coupled regulatory pathway between HDL and
apoB Lps through hepatic ABCA1. The combined results suggest that, in addition to its well
recognized role in HDL biogenesis, hepatic ABCA1 plays a significant and complex role in
apoB LP metabolism.
Previously, we reported that silencing of ABCA1 in rat hepatoma cells decreased formation of
large (>10-nm diameter) nascent HDL particles, increased secretion of large, buoyant TGenriched VLDL, and attenuated PI3K activation (12). We further demonstrated that the addition

of nascent HDL particles, the product of ABCA1-mediated lipidation of apoA-I, to ABCA1silenced hepatoma cells reversed the blockage of PI3K activation and restored the basal rate of
TG secretion. The present study demonstrates the physiological relevance of our previous in
vitro observations using rat hepatoma cells and suggests a new mechanism for the elevated
plasma TG concentrations associated with TD. We show that selective hepatic ABCA1
deficiency in mice increases hepatic VLDL TG secretion ex vivo, using isolated liver perfusion
(Fig. 2A) and cultured primary hepatocytes (Fig. 5D), and in vivo, using detergent to block
VLDL catabolism (Fig. 2B). Furthermore, as assessed by both differential ultracentrifugation and
dynamic laser light scatter data, hepatic ABCA1 deficiency resulted in the formation of larger,
TG-enriched VLDL particles (Fig. 4, A and B), similar to our previous findings with rat
hepatoma cells (12). Finally, acute, partial repletion of hepatic ABCA1 expression with
adenovirus resulted in normalization of plasma VLDL TG concentration (Fig. 7, B and F). These
results collectively suggest a mechanistic link between nascent HDL formed by ABCA1 and
hepatic VLDL TG secretion.
The mechanism responsible for ABCA1-mediated regulation of VLDL assembly and secretion
appears to involve a PI3K-dependent pathway based on multiple lines of evidence. First, HSKO
mice demonstrated attenuated phosphorylation of hepatic PI3K p85 and its downstream target,
Akt, in response to both acute injection of insulin- and glucose-stimulated endogenous insulin
release (i.e. fasting-refeeding; Fig. 5, A and B). Second, diminished PI3K activation was
observed in cultured primary hepatocytes from HSKO mice in conjunction with increased TG
secretion (Fig. 5D). Third, plasma TG concentrations of WT mice were elevated to levels similar
to those of HSKO mice after acute in vivo inhibition of PI3K with wortmannin (Fig. 5C). Finally,
partial adenoviral repletion of hepatic ABCA1 rescued PI3K activation and normalized plasma
TG concentrations (Fig. 7, A and F). These results, along with our previous in vitro data (12),
firmly establish a mechanistic link through which hepatic ABCA1 expression regulates hepatic
PI3K activity, hepatic TG secretion, and plasma TG concentration.
The relationship between VLDL particle assembly and PI3K has been noted previously and, in
part, underlies the ability of insulin to acutely regulate hepatic VLDL TG output (28,–30). The
interface between PI3K-dependent signaling and apoB assembly and secretion is not known in
detail, although in some studies, insulin-mediated signaling, via PI3K and Akt, regulates MTP
expression and, hence, VLDL particle number and size (18, 29, 31, 32). Although MTP is the
target for some forms of PI3K-mediated regulation of VLDL assembly (32), MTP expression
was unaffected by ABCA1 deficiency in this study (Fig. 4E) or by silencing of ABCA1 in rat
hepatoma cells in our previous study (12), suggesting that other mechanisms are operational.
VLDL particle assembly occurs in two steps: the co-translational lipidation of apoB by MTP to
form a small, dense apoB-containing pre-VLDL, followed by a pre-VLDL particle fusion with
TG lipid droplets in the secretory pathway to form mature VLDL particles (33, 34). Several
studies have indicated that the insulin/PI3K effects on VLDL production occur during the
second, pre-VLDL enlargement step of particle assembly (28, 30). The current studies
demonstrate that VLDL from HSKO mice is more buoyant and of larger diameter than that of
WT mice, which is also consistent with ABCA1/PI3K exerting effects during the second step of
VLDL assembly. Because PI3K is present in the endoplasmic reticulum and Golgi, is involved in
intracellular vesicular trafficking, and is increased with insulin stimulation (29, 35, 36), we

hypothesize that the lack of ABCA1 in hepatocytes and the resultant attenuation of PI3K
activation results in slower VLDL transit through the secretory pathway, allowing additional
time for second step VLDL particle expansion. This hypothesis is supported by the observations
of defective lipid and vesicular trafficking from the Golgi to the plasma membrane in fibroblasts
from TD subjects (37,–40).
Reduced LPL activity has also been suggested to explain the elevated TG levels in TD subjects.
For example, Wang et al. (10) showed that VLDL from TD subjects was enriched with apoA-II
and apoC-III, compared with VLDL from normolipidemic subjects, resulting in a reduced lipase
accessibility. Consistent with this notion, Kyreos et al. (41) recently showed that adenoviral
overexpression of human apoC-III in apoE KO and ABCA1 KO mice induces
hypertriglyceridemia due to low LPL reactivity of apoC-III-enriched VLDL. In addition to
possible effects on VLDL substrate, our mouse model also showed that both HL and LPL were
markedly reduced upon deletion of hepatic ABCA1 (Fig. 2C). Therefore, it is likely that the
decrease in HL and LPL in HSKO mice contributed, in large part, to the increase in plasma TG
and apoB48 levels observed in the postprandial state (Figs. 1, B and C, and and22D). These
findings may explain why elevated plasma TG levels in TD patients are more evident
postprandially (9).
Despite elevated plasma TG concentrations, TD subjects have LDL concentrations that are
reduced by ∼40–50% (8). Schaefer et al. (42) demonstrated that this was due to a 2-fold increase
in FCR of LDL. Supporting this finding, Zha et al. (43) reported enhanced uptake of LDL by
fibroblasts from TD subjects that appeared related to increased endocytosis. Similar to TD
subjects, HSKO mice demonstrated a 2-fold increased removal rate of LDL tracer from plasma
compared with WT mice (Fig. 6A). The increased catabolism of LDL probably resulted from the
2.5-fold increase in expression (mRNA and protein) of hepatic LDLr (Fig. 6, B and C). The
increase in hepatic LDLr expression in HSKO mice appears unrelated to hepatic sterol content,
because chow-fed WT and HSKO mice had similar hepatic lipid content and expression of
cholesterol-sensitive genes (supplemental Fig. 1A). Additional evidence to support our
conclusion that increased hepatic LDLr expression is responsible for the decreased plasma LDL
concentrations in HSKO mice comes from our studies in which HSKO mice were crossed into
the LDLrKO background. In the absence of whole-body LDLr expression, we observed similar
plasma LDL concentrations in LDLrKO and HSKO-LDLrKO mice (Fig. 6F), although plasma
TG concentrations were still significantly higher in HSKO-LDLrKO mice relative to LDLrKO
mice. These results suggest that two separate mechanisms, increased hepatic LDLr expression
and increased hepatic TG secretion, are responsible for the reduced plasma LDL and increased
plasma TG concentrations, observed under conditions of hepatic ABCA1 expression deficiency.
Transgenic LDLrKO mice with 2.3-fold overexpression of ABCA1 protein in the liver displayed
significantly increased plasma VLDL, LDL, and HDL cholesterol concentrations, increased
apoA-I and apoB levels, delayed clearance of VLDL and LDL tracers, and an increase in
atherosclerosis (44). These data led to the hypothesis that liver ABCA1 may play a
proatherogenic role in vivo, resulting from its dramatic effects on the metabolism of apoBcontaining lipoproteins. These mice also displayed increased plasma TG concentrations, perhaps
due to a small but significantly delayed clearance of plasma VLDL particles caused by their
cholesterol enrichment. However, a more modest overexpression of ABCA1 protein (∼25%)

using the endogenous ABCA1 promoter in LDLrKO mice resulted in no significant increase in
apoB-containing lipoprotein concentration and a significant reduction in atherosclerosis,
probably due to an increase in macrophage ABCA1 protein expression (45). The reasons for the
apparently discrepant impact of ABCA1 overexpression on LDL concentrations and
atherosclerosis in LDLrKO mice are 2-fold. First, the regulatory elements controlling the sites
and regulation of ABCA1 expression were different in the two studies. Second, the extent of
ABCA1 overexpression was ∼10-fold higher when the apoE promoter was used (∼2.5-fold over
expression) versus the endogenous ABCA1 promoter (0.25-fold increase). Indeed, when a 2.6fold overexpression of ABCA1 was achieved in the liver using a cytomegalovirus promoter in
adenovirus, significant increases in the concentration of plasma proatherogenic apoB-containing
lipoproteins as well as HDL cholesterol were observed (22). Taken together, these studies
complement our data and demonstrate that when hepatic ABCA1 is overexpressed to a sufficient
extent, LDL concentrations are elevated, whereas liver-specific deletion of ABCA1 results in
reduced plasma LDL concentrations.
In summary, our data support an important and emerging role for hepatic ABCA1 expression in
the production and catabolism of apoB lipoproteins and suggest new mechanisms to account for
the increased plasma TG and decreased LDL concentrations observed in TD subjects.
Furthermore, the decreased LDL levels may explain why some TD subjects have only minimally
increased risk of coronary heart disease despite having extremely low plasma HDL levels (4).
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Figures and Tables
FIGURE 1.

Targeted deletion of hepatocyte ABCA1 induces hypertriglyceridemia. Plasma was collected
from fasted (A) and non-fasted (B–E) wild type (+/+), heterozygous (Hetero), and homozygous
HSKO mice. A, fasted (6 h) plasma TG concentrations, mean ± S.E. ns, not significant. B, nonfasted plasma TG concentrations, mean ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001. C,
Western blot analysis of hepatic ABCA1 expression and plasma levels of apoB100 and apoB48.
Twenty μl of plasma were immunoprecipitated with anti-human apoB antibody, and the
immunoprecipitates were fractionated by SDS-PAGE and Western blotted using the same antihuman apoB antibody. D, FPLC profiles of cholesterol (top) and triglyceride (bottom) in pooled
plasma (450 μl; n = 6/genotype). Insets show the VLDL cholesterol (top) and LDL TG (bottom)
results. E, Western blot analysis of 25 μl of selected FPLC fractions corresponding to D.

FIGURE 2.

Selective deletion of hepatocyte ABCA1 increases hepatic TG secretion and reduces postheparin lipase activity. A, TG mass accumulation per g of liver during isolated recirculating
liver perfusion of WT (+/+) (n = 6) and HSKO (n = 5) mice. Data points denote mean TG ± S.E.
of mice of the indicated genotype at each time point; the line of best fit, determined by linear
regression analysis, is shown for both genotypes. Accumulation rates (μg/g liver/min) of TG
were derived by linear regression analysis of the slope of the plot for each mouse. The mean ±
S.E. accumulation rate was 1.87 ± 0.07 and 3.40 ± 0.20 μg/min/g liver for WT and HSKO mice,
respectively. B, appearance of newly synthesized plasma TG and apoB after detergent block (n =
3 for each genotype). Data points denote the mean ± S.E. of radiolabeled TG in 100 μl of plasma;
the line of best fit, determined by linear regression analysis, is shown for both genotypes.
Accumulation rates were derived by linear regression analysis of the slope of the plot for each
mouse; mean ± S.E. accumulation rates ([3H]TG/100 μl of plasma/h) of TG were 51,550 ± 6,205
and 136,500 ± 12,480 for WT and HSKO mice, respectively. Accumulation of newly
synthesized and secreted plasma apoB in the terminal plasma sample was determined after
immunoprecipitation with anti-apoB antiserum, SDS-PAGE separation of proteins, and
PhosphorImager analysis. Relative PhosphorImager intensity of total apoB (apoB100 + B48),
normalized to a WT mouse sample, is shown below the gel. C, plasma isolated 15 min after
intravenous heparin injection (300 units/kg) was used to measure the HL and LPL activity in WT
(+/+, n = 8) and HSKO (n = 7) mice. D, plasma TG and TC concentration after oral gavage of

olive oil (150 μl) in WT (+/+) and HSKO mice (n = 4/group). Data expressed in mean ± S.E. *, p
< 0.05; ***, p < 0.001 by Student's t test.

FIGURE 3.

Targeted deletion of hepatocyte ABCA1 does not alter liver lipid content, gene expression,
or lipid fatty acid composition. A, liver lipid content (TG, TC, free cholesterol (FC), and
cholesteryl ester (CE)) in chow-fed wild type (+/+, n = 11) and HSKO (n = 9) mice was analyzed
by enzymatic assays, and results were normalized to liver wet weight. B, mRNA expression of
genes related to lipid metabolism were analyzed by quantitative real-time PCR and normalized to

GAPDH expression. Mean ± S.E., n = 6/genotype. C, fatty acid (FA) composition of hepatic
cholesteryl ester, TG, and phospholipid (PL) from wild type (+/+, n = 3) and HSKO (+/+, n = 3)
mice was determined by gas-liquid chromatography. Percentage distribution of polyunsaturated
fatty acids (PUFA; n-3 and n-6), monounsaturated fatty acids (MUFA), and saturated fatty acids
(SFA) is shown in each column. D, hepatic free fatty acid (FFA) content was determined in liver
from wild type and HSKO mice (n = 5/group) by enzymatic assay. Data are expressed as mean ±
S.E. ns, not significant at p = 0.05 by Student's t test.

FIGURE 4.

Targeted deletion of hepatocyte ABCA1 increases plasma VLDL size. A, fractionation of
VLDL1 (Sf = 100–400) and VLDL2 (Sf = 20–100) in pooled plasma (n = 3/genotype, 200 μl
total) by density gradient ultracentrifugation. VLDL1 and -2 were then assayed for TG
concentration. B, VLDL size determination of pooled VLDL1 and VLDL2 fractions (equal
volumes) by dynamic laser light scattering. C, VLDL fractions from A were concentrated, and 4
μg of VLDL protein was separated by 4–16% SDS-PAGE and transferred to polyvinylidene
difluoride membrane for Western blot analysis of apoB, apoE, and apoA-I.

FIGURE 5.

Targeted deletion of hepatocyte ABCA1 induces defective PI3K signaling. A, Western blot
analysis of liver ABCA1, PI3K p85, and phospho-PI3K p85 expression 5 min after insulin (5
units/kg) injection into the portal vein. B, Western blot analysis of liver phospho-PI3K p85 (pPI3Kp85), phospho-Akt (p-Akt), and total Akt (t-Akt) expression after fasting or
fasting/refeeding of mice. C, PI3K inhibitor, wortmannin (1.5 μg/g body weight in DMSO), or
DMSO alone was injected into the peritoneal cavity of mice 1 h prior to injection of detergent
(1000 mg of poloxamer 407/kg of body weight) to block lipolysis and 7 μCi of [35S]Cys/Met/g of
body weight as described under “Experimental Procedures.” Plasma TG concentration (mean ±
S.E., n = 3) and apoB phosphor image (bottom) were analyzed 2 h after detergent block. Relative
PhosphorImager intensity of apoB is shown below each lane. Values were normalized to the
apoB100 band in the DMSO-treated WT mouse. D, triglyceride secretion ([3H]TG) and PI3K
phosphorylation from isolated primary hepatocytes. E, quantification of MTP expression in
livers of WT and HSKO mice by real-time PCR (mRNA pool from 3 mice/genotype; top) and

Western blot analysis (n = 3 of each genotype; bottom). Data were normalized to GAPDH
expression. Data are expressed as mean ± S.E. *, p < 0.05; ***, p < 0.001 by Student's t test. ns,
not significant.

FIGURE 6.

Hepatocyte-specific deletion of ABCA1 induces rapid LDL clearance from plasma. LDL
from LDLrKO mice was isolated and radioiodinated with 125I. A, 125I-LDL tracer was injected
into WT and HSKO recipient mice, and periodic blood samples were taken to quantify the
amount of tracer remaining in plasma (results normalized to the 2 min time point). Mean ± S.E.,
n = 4. FCR values (mean ± S.E.) were calculated from individual plasma die-away curves using
a biexponential curve-fitting program. ***, p < 0.001 by Student's t test. B, real-time PCR
quantification of hepatic ABCA1 and LDLr mRNA levels. Data were normalized to GAPDH
expression (mean ± S.E.; n = 6). C, liver protein (50 μg) from WT and HSKO mice was
fractionated by SDS-PAGE and analyzed for expression of ABCA1, LDLr, and GAPDH by
Western blot. Relative quantification of the blot is shown on the right. Data are expressed as
mean ± S.E. D, effects of hepatic ABCA1 deficiency on non-fasting plasma TG (top) and TC
(bottom) in the LDLrKO background. Shown are wild type (LDLrKO, +/+), heterozygous
(LDLrKO, Hetero), and homozygous HSKO (LDLrKO, HSKO) mice (n = 4/group), mean ± S.E.
F, FPLC-cholesterol profiles of pooled plasma of wild type (LDLrKO, +/+) and HSKO
(LDLrKO, HSKO) mice in the LDLrKO background (n = 4/group). Inset, expanded VLDL
region. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by Student's t test (A and B) or analysis of
variance (D).

FIGURE 7.

Adenoviral overexpression of ABCA1 normalizes plasma TG concentrations in HSKO
mice. Mice were fed an HF diet for 8 weeks before intravenous injection of either Ad-AP or AdABCA1. Mice were sacrificed 3 days later to collect liver and plasma samples. A, Western blot

analysis of hepatic ABCA1, LDLr, phosphorylated PI3K (p-PI3K), and total PI3K (t-PI3K)
expression in wild type (WT; +/+) and HSKO mice. ABCA1 and LDLr expression level were
quantified (normalized to GAPDH). Expression relative to control mice is denoted below each
band. B, plasma concentrations of TG and TC in WT and HSKO mice (n = 4/group) after
adenovirus injection. Data are expressed as mean ± S.E. *, p < 0.05; ***, p < 0.001 by Student's t
test. C, FPLC-cholesterol profile from pooled plasma of WT mice (n = 4) after adenoviral
administration. D, FPCL-cholesterol profile from pooled plasma of HSKO mice (n = 4) after
adenovirus administration. E, FPLC-TG profile from pooled plasma of WT mice (n = 4) after
adenovirus administration. F, FPLC-TG profile from pooled plasma of HSKO mice (n = 4) after
adenovirus administration. G, hepatic content of TG, TC, FC, and cholesteryl ester (CE) in WT
and HSKO mice (n = 4/group). Data are expressed as mean ± S.E. *, p < 0.05 by one-way
analysis of variance with Tukey's multiple comparison.
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Table 1. Gene-specific primers for qPCR
Target mRNA

Forward Primer

Reverse Primer

ABCG5

TGG CCC TGC TCA GCA TCT

ATT TTT AAA GGA ATG GGC ATC TCT T

LRP

TGGGTCTCCCGAAATCTGTT

CCACCGCATTCTTGAAGGA

LDLr

AGGCTGTGGGCTCCATAGG

TGCGGTCCAGGGTCATCT

SREBP1c

GGCCGAGATGTGCGAACT

TTGTTGATGAGCTGGAGCATGT

PPARα

ACAAGGCCTCAGGGTACCA

GCCGAAAGAAGCCCTTACAG

PPARγ

CACAATGCCATCAGGTTTGG

GCTGGTCGATATCACTGGAGATC

PGC1α

AACCACACCCACAGGATCAGA

TCTTCGCTTTATTGCTCCATGA

FXRα

TGGGCTCCGAATCCTCTTAGA

TGGTCCTCAAATAAGATCCTTGG

MTP

CCTACCAGGCCCAACAAGAC

CGCTCAATTTTGCATGTATCC

Supplement Fig. 1. A. Real time PCR quantification of hepatic mRNA levels of ABCG5, ABCG1, LRP
and SRB-1. Data were normalized to GAPDH expression (mean ± SEM; n=3 per genotype). B. Western
blot analysis of hepatic SR-B1 and EL expression in WT and HSKO mice (n=3).
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